Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nkarta, Inc. filings document the regulatory record of a clinical-stage biotechnology company advancing engineered NK cell therapies for autoimmune disease. Recent 8-K reports disclose quarterly and annual financial results, corporate highlights, and clinical-program references for NKX019 and the Ntrust studies.
The company’s proxy materials cover annual meeting governance, director elections, auditor ratification, executive compensation votes, and stockholder voting mechanics. Other filings describe capital-raising infrastructure, including a Form S-3 registration statement and an at-the-market sales agreement for common stock, as well as emerging growth company reporting status and related Exchange Act disclosures.
Nkarta, Inc. furnished an update on its business by announcing that it issued a press release with financial results for the third quarter ended September 30, 2025. The company provided this update via a current report and attached the press release as Exhibit 99.1 titled “Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights.”
The disclosure states that the information, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf engineered NK cell therapies, with lead program NKX019 targeting CD19 for autoimmune diseases. The company continues multiple Phase 1 and investigator-sponsored trials while reprioritizing its pipeline and modifying lymphodepleting conditioning for ongoing studies.
For the three months ended June 30, 2025 Nkarta reported a net loss of $22.98 million and for the six months a net loss of $54.96 million. Research and development was $20.78 million in the quarter and $44.95 million for six months; total operating expenses were $27.19 million in the quarter. As of June 30, 2025 the company had an accumulated deficit of $599.2 million and reported $334.0 million of cash, cash equivalents, restricted cash and investments, which management believes is sufficient to fund operations for at least 12 months.
Operational actions include a March 26, 2025 reduction in force of 53 positions (~34% of workforce) with related severance of approximately $5.4 million, deprioritization of certain programs, and the appointment of Shawn Rose, M.D., Ph.D., as Chief Medical Officer effective June 23, 2025. The balance sheet shows total assets of $448.3 million and operating lease liabilities of $78.5 million.
Nkarta, Inc. furnished a press release announcing its financial results for the second quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Current Report on Form 8-K. The Form 8-K also includes a Cover Page Interactive Data File as Exhibit 104. The filing states the Item 2.02 disclosure (including Exhibit 99.1) is being furnished and shall not be deemed "filed" under the Exchange Act nor incorporated by reference into filings under the Securities Act or the Exchange Act unless the company expressly states otherwise.
The filing identifies the registrant as a Delaware corporation (Commission File Number 001-39370; EIN 47-4515206), lists its principal executive office in South San Francisco, California, and shows the company’s common stock trades as NKTX on the Nasdaq Global Select Market. The report is signed by Nadir Mahmood as President.
Nkarta reported a significant insider transaction involving Chief Medical Officer and Head of R&D, Shawn Marshall Rose. On June 23, 2025, Rose was granted stock options to purchase 500,000 shares of common stock at an exercise price of $1.75 per share.
The stock options have a structured vesting schedule:
- 25% of the options vest on July 23, 2026
- Remaining 75% vest in 36 equal monthly installments following June 23, 2026
- Options expire on June 22, 2035
This grant suggests a long-term retention strategy for a key executive, with the low exercise price potentially indicating recent stock price challenges or an incentive-focused compensation structure. The substantial size of the grant (500,000 shares) reflects the senior leadership position and importance of the R&D function to the company.
Form 3 Initial Statement of Beneficial Ownership filed for Nkarta (NKTX) on June 28, 2025, reporting the beneficial ownership status of Shawn Marshall Rose, who has been appointed as the company's Chief Medical Officer and Head of Research & Development.
Key details:
- Filing Date: June 28, 2025
- Event Date: June 23, 2025
- Location: South San Francisco, CA
- Filing Type: Individual filing
- Current Holdings: No securities beneficially owned
This Form 3 indicates that the executive currently holds no derivative or non-derivative securities in the company. The filing was signed by Bridgette Housley as Attorney-in-Fact on June 25, 2025, and includes a Power of Attorney as Exhibit 24.
Nkarta, Inc. (NKTX) – Form 4 Insider Transaction Overview
CEO and Director Paul J. Hastings disclosed the sale of 1,790 common shares on 06/18/2025 at a weighted-average price of $1.79. The transaction was automatically executed to satisfy tax-withholding obligations triggered by the vesting and settlement of Restricted Stock Units and therefore was not a discretionary sale. Following the sale, Hastings continues to beneficially own 320,069 shares, which includes 2,000 shares purchased under Nkarta’s 2020 Employee Stock Purchase Plan on 05/31/2025.
No derivative securities were acquired or disposed of, and no additional transactions were reported. Given the small size of the sale—roughly 0.56% of the executive’s total holdings—the filing appears routine and does not signal any change in corporate strategy, financial position, or insider sentiment.